KVUE · Intrinsic value
Is Kenvue Inc. (KVUE) overvalued or undervalued?
As of Oct 20, 2026, TickerWorth's valuation lenses put Kenvue Inc. (KVUE) at $8.51 – $32.87, too broad a range to say where the delayed market price of $18.87 sits in it, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 20, 2026 · How these pages are made
What is KVUE worth?
- Fair-value range
- $8.51 – $32.87
- Market price
- $18.87
- Gap to fair value
- —
- Verdict
- Too wide to call
Reverse DCF: Today's price implies revenue growth of 1.4% a year for 5 years; our model assumes 2.8% a year on average over the same horizon.
What is KVUE's TickerWorth Score?
Scores higher than most companies we compare it with
Compared with Consumer Defensive companies in US
Its strongest point: recent price trend has been strong.
- Value · 53 of 100
Cheaper than 53% of Consumer Defensive companies in US
- Price vs worth · 52 of 100
- Quality · 65 of 100
More profitable than 65% of Consumer Defensive companies in US
- Financial health · 53 of 100
Financially stronger than 53% of Consumer Defensive companies in US
- Growth · 52 of 100
Growing faster than 52% of Consumer Defensive companies in US
- Momentum · 85 of 100
Outperformed 85% of Consumer Defensive companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why KVUE gets a range, not one number
At a recent price of $18.87, Kenvue Inc. (KVUE) sits inside a range too wide to call either way: our valuation lenses put the business somewhere between $8.51 and $32.87 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts Kenvue Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 7.0%, with a long-run terminal growth rate of 2.5%. About 81% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 1.4% annual revenue growth for KVUE. Our base case instead compounds to about 2.8% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, KVUE's modeled DCF value ranges from about $11.40 to $46.80 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Kenvue Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of KVUE's intrinsic value. Figures update as new filings and prices come in.
Every input behind KVUE's DCF
| Input | Value |
|---|---|
| Base-year revenueKenvue Inc. FY2025 10-K (accession 0001944048-26-000030): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $15,124,000,000 |
| Base EBIT marginKenvue Inc. FY2025 10-K (accession 0001944048-26-000030): us-gaap:OperatingIncomeLoss 2,414,000,000 / revenue 15,124,000,000 = 15.96%, FY2025. | 16.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 2% → 2% → 3% → 3% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.43 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesKenvue Inc. FY2025 10-K (accession 0001944048-26-000030): WeightedAverageNumberOfDilutedSharesOutstanding = 1,924,000,000 shares, FY2025. | 1,924M |
| Market priceBackup price feed · as of 2026-10-20 12:17 UTC | $18.87 |
Change KVUE's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Kenvue Inc. do?
What does it do?
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in the Household & Personal Products industry (Consumer Defensive sector), headquartered in United States. The company employs roughly 21,780 people.
How does it make money?
The business turns $15.1B in annual revenue into profit. Out of every $100 of sales, about $19 is left as operating profit (operating margin of 19.4%), after a 58% gross margin on the products/services it sells. After all costs, taxes and interest, 10.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.8× equity), can just cover its short-term bills (1.0× current ratio), and is currently profitable.
Who at KVUE filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Lawson Carlton | Group President EMEA & LA | Grant / award | $629,468.40 | Form 4 for Lawson Carlton (opens sec.gov in a new tab) | |
| Orlando Matthew | General Counsel | Grant / award | $614,968.80 | Form 4 for Orlando Matthew (opens sec.gov in a new tab) | |
| Orlando Matthew | General Counsel | Shares withheld (tax) | $253,682.80 | Form 4 for Orlando Matthew (opens sec.gov in a new tab) | |
| Stevens Meredith | Chief Operations Officer | Grant / award | $614,968.80 | Form 4 for Stevens Meredith (opens sec.gov in a new tab) | |
| Stevens Meredith | Chief Operations Officer | Shares withheld (tax) | $261,302.40 | Form 4 for Stevens Meredith (opens sec.gov in a new tab) | |
| Tillett Caroline | Chief Scientific Officer | Grant / award | $425,390.40 | Form 4 for Tillett Caroline (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is KVUE's intrinsic value?
TickerWorth's valuation lenses put Kenvue Inc. (KVUE) between $8.51 and $32.87 per share, versus a market price of $18.87. They disagree too widely for us to state a single fair value, so we publish the range.
Is KVUE overvalued or undervalued?
At $18.87 the price sits inside a range too wide to call either way. We don't call KVUE overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for KVUE?
A WACC of 7.0% and a terminal growth rate of 2.5%.
Is Kenvue stock undervalued?
TickerWorth's fair-value range for Kenvue Inc. (KVUE) is $8.51 – $32.87 against a market price of $18.87. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
Kenvue (KVUE) DCF valuation and fair value
Our fair-value range for Kenvue Inc. (KVUE) is $8.51 – $32.87, built on a 7.0% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Kenvue stock?
Today's price implies revenue growth of 1.4% a year for 5 years; our model assumes 2.8% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $18.87. A model estimate, not investment advice.
Kenvue (KVUE) insider trading
The most recent insider filing (SEC Form 4) for Kenvue Inc. (KVUE): Lawson Carlton, Group President EMEA & LA, grant / award on 2026-10-02. The latest filings are listed on this page. A disclosure, not a signal to trade.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.